These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26546259)

  • 1. Safety and immunogenicity of ricin vaccine, RVEc™, in a Phase 1 clinical trial.
    Pittman PR; Reisler RB; Lindsey CY; Güereña F; Rivard R; Clizbe DP; Chambers M; Norris S; Smith LA
    Vaccine; 2015 Dec; 33(51):7299-7306. PubMed ID: 26546259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Process development and cGMP manufacturing of a recombinant ricin vaccine: an effective and stable recombinant ricin A-chain vaccine-RVEc™.
    Meagher MM; Seravalli JG; Swanson ST; Ladd RG; Khasa YP; Inan M; Harner JC; Johnson SK; Van Cott K; Lindsey C; Wannemacher R; Smith LA
    Biotechnol Prog; 2011 Jul; 27(4):1036-47. PubMed ID: 21630488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.
    Frey SE; Lottenbach KR; Hill H; Blevins TP; Yu Y; Zhang Y; Brenneman KE; Kelly-Aehle SM; McDonald C; Jansen A; Curtiss R
    Vaccine; 2013 Oct; 31(42):4874-80. PubMed ID: 23916987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults.
    Seiberling M; Bologa M; Brookes R; Ochs M; Go K; Neveu D; Kamtchoua T; Lashley P; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7455-60. PubMed ID: 23131206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study.
    Brooks WA; Chang LJ; Sheng X; Hopfer R;
    Vaccine; 2015 Aug; 33(36):4610-7. PubMed ID: 26143615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
    Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
    Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
    Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
    Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL
    Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.
    Landrum ML; Lalani T; Niknian M; Maguire JD; Hospenthal DR; Fattom A; Taylor K; Fraser J; Wilkins K; Ellis MW; Kessler PD; Fahim RE; Tribble DR
    Hum Vaccin Immunother; 2017 Apr; 13(4):791-801. PubMed ID: 28010246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers.
    Kang G; Ma F; Chen H; Yang Y; Guo S; Wang Z; Liang X; Li L; Cui F; Zhang L
    Vaccine; 2015 Aug; 33(33):4093-9. PubMed ID: 26144895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in biological threat agent vaccine development: a repeat-dose toxicity study of a recombinant ricin toxin A-chain (rRTA) 1-33/44-198 vaccine (RVEc) in male and female New Zealand white rabbits.
    McLain DE; Horn TL; Detrisac CJ; Lindsey CY; Smith LA
    Int J Toxicol; 2011 Mar; 30(2):143-52. PubMed ID: 21378370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults.
    Diemert DJ; Freire J; Valente V; Fraga CG; Talles F; Grahek S; Campbell D; Jariwala A; Periago MV; Enk M; Gazzinelli MF; Bottazzi ME; Hamilton R; Brelsford J; Yakovleva A; Li G; Peng J; Correa-Oliveira R; Hotez P; Bethony J
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005574. PubMed ID: 28464026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72.
    Kende M; Tan X; Wlazlowski C; Williams R; Lindsey C; Del Giudice G
    Vaccine; 2007 Apr; 25(16):3219-27. PubMed ID: 17343960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an o-pthalaldehyde (OPA) assay to measure protein content in Ricin Vaccine E. coli (RVEc™).
    Montgomery VA; Lindsey CY; Smith LA; Webb RP
    Vaccine; 2021 Jan; 39(3):564-570. PubMed ID: 33339670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial.
    ; Cape S; Chaudhari A; Vaidya V; Mulay R; Agarkhedkar S; Shermer C; Collins M; Anderson R; Agarkhedkar S; Kulkarni PS; Winston S; Sievers R; Dhere RM; Gunale B; Powell K; Rota PA; Papania M
    Vaccine; 2014 Nov; 32(50):6791-7. PubMed ID: 25446830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.